PRAC recommends revoking marketing authorisation of ulipristal acetate for uterine fibroids

View source ↗

Summary

The European Medicines Agency's PRAC recommended revoking the marketing authorisation of ulipristal acetate for treating uterine fibroids due to safety concerns…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Fibroids

Drugs mentioned

• Ulipristal acetate (ulipristal acetate)